However, the rising popularity of GLP-1 drugs, which are highly effective in helping people lose weight and also reduce the ...

Return on Equity (ROE): DexCom's ROE stands out, surpassing industry averages. With an impressive ROE of 6.1%, the company demonstrates effective use of equity capital and strong financial ...

Key Insights The projected fair value for DexCom is US$123 based on 2 Stage Free Cash Flow to Equity Current share... DexCom (DXCM) doesn't possess the right combination of the two key ingredients ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket on Monday after the company set its financial forecast for 2025, projecting adjusted gross profit margin of around 64% – 65% on revenue of $4.60B ...

For 2025, Dexcom expects revenue of $4.6 billion. MedTech Dive caught up with Sayer for more details on Dexcom’s strategy for over-the-counter sensors and other plans for this year, including a ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...

SAN FRANCISCO—After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said ... from 12% to 6%, you guys would ...

Shares of DexCom Inc. DXCM advanced 1.55% to $80.40 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.83% to 5,949.91 ...